(SHLTN) S H L Telemedicine - Ratings and Ratios

SHL Telemedicine Ltd. is a healthcare technology company that develops and markets innovative telemedicine solutions globally, with a focus on cardiac monitoring and remote patient care. The companys product portfolio includes a range of personal ECG devices, such as SmartHeart, CardioSenC, and CardioB, which enable real-time monitoring and transmission of medical data to healthcare professionals.

The companys telemedicine services and devices cater to a diverse customer base, including physicians, hospitals, health insurance funds, and patients. SHL Telemedicine has established strategic partnerships with renowned institutions like the Mayo Clinic, Hebrew University of Jerusalem, and Hadassah Medical Center to advance its research and development capabilities.

From a technical analysis perspective, the stock has shown a relatively stable trend, with its 20-day simple moving average (SMA) at 2.00 and 50-day SMA at 2.05. However, the 200-day SMA at 2.57 indicates a potential resistance level. The Average True Range (ATR) of 0.22 represents a volatility of 10.81%, suggesting a moderate level of price fluctuations. Given the current price of 2.04, a potential trading range could be between 1.80 and 2.20, with a possible breakout above 2.57 if the company announces positive news or achieves significant milestones.

Fundamentally, SHL Telemedicines market capitalization stands at 33.61M CHF, with a negative return on equity (RoE) of -12.55%. The absence of a price-to-earnings (P/E) ratio indicates that the company is likely loss-making. However, the companys innovative products and strategic partnerships could potentially drive future growth. Based on the current trends and available data, a forecast for the stock could be: a potential short-term trading range between 1.80 and 2.20, with a medium-term target of 2.57, contingent upon the companys ability to improve its financial performance and achieve key milestones.

Taking into account both technical and fundamental data, a potential investment thesis for SHL Telemedicine could be: the companys innovative telemedicine solutions, strategic partnerships, and potential for future growth could drive the stock price upwards, potentially breaking through the 2.57 resistance level. However, investors should be cautious of the companys current financial performance and the competitive landscape in the healthcare technology sector.